Invitae Corp
NYSE:NVTA
Intrinsic Value
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. [ Read More ]
The intrinsic value of one
NVTA
stock under the Base Case scenario is
4.49
USD.
Compared to the current market price of 0.019 USD,
Invitae Corp
is
Undervalued by 100%.
Invitae Corp's market capitalization is 5.4m USD.
NVTA stock price is 0.019 USD.
NVTA stock price (0.019 USD) is 100% less than its Intrinsic Value (4.49 USD).
NVTA. Open DCF Valuation
NVTA stock price (0.019 USD) is 100% less than its Relative Value (4.49 USD). Open Relative Valuation
NVTA.
NVTA has positive three-year average ROIC (Return on Invested Capital): 9%. The company is efficient at using invested capital to generate operating income.
NVTA's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
NVTA's Revenue has dropped by 7% over the past 12 months.
NVTA has positive Gross Profit for the last twelve months.
NVTA's ROE (Return on Equity) has significantly increased in the last 3 years from -45% to 312%.
NVTA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -30% to 214%.
NVTA's Revenue has been growing by an exceptional 25% per year for the last 3 years.
NVTA has positive Operating Income for the last twelve months.
NVTA has negative Net Income for the last twelve months.
NVTA's ROE (Return on Equity) for the past 12 months is very high and is equal to 312%.
NVTA's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 214%.
NVTA's short-term assets (378m USD) exceed its short-term liabilties (158m USD).
NVTA has positive Net Debt. This means that the company has more debt (1B USD) than cash and short-term investments (255m USD).
NVTA has negative Free Cash Flow for the last twelve months.
NVTA's long-term liabilties (2B USD) exceed its long-term assets (535m USD).
NVTA has negative three-year average ROE (Return on Equity): -128%. The company is not efficient at transforming stockholders' equity into net income.
NVTA's D/E (Debt to Equity) is very low and is equal to -1.22.
NVTA's Altman Z-Score is very low and is equal to -4.02.
Fundamental Analysis
Invitae Corp
Balance Sheet Decomposition
Invitae Corp
| Current Assets | 378.4m |
| Cash & Short-Term Investments | 254.6m |
| Receivables | 82.5m |
| Other Current Assets | 41.3m |
| Non-Current Assets | 156.7m |
| PP&E | 127.1m |
| Other Non-Current Assets | 29.6m |
| Current Liabilities | 158.4m |
| Accounts Payable | 25.2m |
| Accrued Liabilities | 92.8m |
| Other Current Liabilities | 40.4m |
| Non-Current Liabilities | 1.5B |
| Long-Term Debt | 1.3B |
| Other Non-Current Liabilities | 135.2m |
Earnings Waterfall
Invitae Corp
|
Revenue
|
481.6m
USD
|
|
Cost of Revenue
|
-350.9m
USD
|
|
Gross Profit
|
130.7m
USD
|
|
Operating Expenses
|
1.7B
USD
|
|
Operating Income
|
1.8B
USD
|
|
Other Expenses
|
-3.3B
USD
|
|
Net Income
|
-1.4B
USD
|
Free Cash Flow Analysis
Invitae Corp
What is Free Cash Flow?
NVTA Profitability Score
Profitability Due Diligence
Invitae Corp's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Invitae Corp's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
NVTA Solvency Score
Solvency Due Diligence
Invitae Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Invitae Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVTA Price Targets Summary
Invitae Corp
Ownership
NVTA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NVTA Price
Invitae Corp
| Average Annual Return | -3.46% |
| Standard Deviation of Annual Returns | 116.22% |
| Max Drawdown | -100% |
| Market Capitalization | 5.4m USD |
| Shares Outstanding | 286 492 992 |
| Percentage of Shares Shorted | 26.2% |
Company Profile
Invitae Corp
Country
Industry
Market Cap
Dividend Yield
Description
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. The company is headquartered in San Francisco, California and currently employs 3,000 full-time employees. The company went IPO on 2015-02-12. The firm is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. The company offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The firm offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.
You don't have any saved screeners yet
